Pursuant to Regulation 30 of Listing Regulations, please find enclosed Press Release Wockhardt s Fifth Novel Antibiotic, Foviscu® (WCK 4282), Matches Gold-Standard Meropenem in pivotal Phase 3 Trial as First-Line Therapies Fail Against Rising Resistance .
WOCKPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Wockhardt announced that its fifth novel antibiotic, Foviscu® (WCK 4282), met the primary endpoint in a pivotal Phase 3 clinical trial, matching the performance of Meropenem, which is the current gold-standard treatment. The trial positions Foviscu as a potential first-line therapy amid growing antibiotic resistance that is causing existing treatments to fail. This marks a key milestone for Wockhardt's anti-infective drug pipeline and addresses a critical unmet medical need. Full trial details and safety data have been shared in the enclosed press release.
Positive development for Wockhardt's pipeline; successful Phase 3 results strengthen the case for future regulatory approvals and potential global commercialization, which could meaningfully expand the company's anti-infective revenue in the coming years.